U.S. FDA approves expanded use of J&J's cancer cell therapy

Friday, 05 April 2024

U.S. FDA approves expanded use of J&J's cancer cell therapy

By Reuters

April 6, 20247:43 AM GMT+4Updated 9 days ago

The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid/File Photo Purchase Licensing Rights, opens new tab

April 5 (Reuters) - The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson (JNJ.N), opens new tab and Legend Biotech's (LEGN.O), opens new tab Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.

Source: Reuters

Member of

dmg events is an international exhibition and conference organiser, publisher and information provider to the Energy, Construction, Plastics, Coatings, Manufacturing, Transport, Security, Interiors and Hospitality industries.